 Martin McCarter
Concepts (788)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 50 | 2024 | 738 | 7.990 |
Why?
| | Esophageal Neoplasms | 28 | 2024 | 298 | 5.580 |
Why?
| | Skin Neoplasms | 34 | 2024 | 829 | 4.880 |
Why?
| | Esophagectomy | 20 | 2024 | 122 | 3.580 |
Why?
| | Adenocarcinoma | 28 | 2024 | 898 | 3.520 |
Why?
| | Sentinel Lymph Node Biopsy | 23 | 2022 | 107 | 2.770 |
Why?
| | Myeloid-Derived Suppressor Cells | 5 | 2024 | 63 | 2.590 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 46 | 2.280 |
Why?
| | Neoadjuvant Therapy | 14 | 2024 | 383 | 1.800 |
Why?
| | Rectal Neoplasms | 8 | 2024 | 136 | 1.760 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 42 | 1.750 |
Why?
| | Pancreatic Neoplasms | 15 | 2024 | 878 | 1.720 |
Why?
| | Dendritic Cells | 13 | 2019 | 478 | 1.690 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2024 | 952 | 1.690 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 377 | 1.670 |
Why?
| | Lymphatic Metastasis | 20 | 2023 | 312 | 1.430 |
Why?
| | Stomach Neoplasms | 5 | 2024 | 97 | 1.360 |
Why?
| | Neoplasm Staging | 32 | 2024 | 1286 | 1.360 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1572 | 1.310 |
Why?
| | Tumor Escape | 4 | 2017 | 38 | 1.270 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 107 | 1.180 |
Why?
| | Colonic Neoplasms | 7 | 2024 | 234 | 1.160 |
Why?
| | Lymph Nodes | 15 | 2023 | 459 | 1.150 |
Why?
| | Humans | 206 | 2025 | 129078 | 1.150 |
Why?
| | Middle Aged | 101 | 2024 | 31024 | 1.130 |
Why?
| | Anus Neoplasms | 3 | 2024 | 30 | 1.110 |
Why?
| | Aged | 85 | 2024 | 22068 | 1.110 |
Why?
| | Neoplasms | 12 | 2024 | 2429 | 1.080 |
Why?
| | Peritoneal Neoplasms | 4 | 2024 | 83 | 1.070 |
Why?
| | Retrospective Studies | 55 | 2024 | 14562 | 1.050 |
Why?
| | Hyperglycemia | 3 | 2020 | 321 | 1.050 |
Why?
| | Intestinal Neoplasms | 2 | 2024 | 28 | 1.020 |
Why?
| | Cytoreduction Surgical Procedures | 5 | 2024 | 61 | 1.010 |
Why?
| | Postoperative Complications | 20 | 2024 | 2497 | 1.010 |
Why?
| | HIV-1 | 16 | 2022 | 840 | 0.990 |
Why?
| | Laparoscopy | 8 | 2024 | 453 | 0.960 |
Why?
| | HIV Infections | 20 | 2022 | 2699 | 0.950 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2021 | 1044 | 0.950 |
Why?
| | Sarcoma | 6 | 2025 | 173 | 0.930 |
Why?
| | Intestine, Small | 2 | 2024 | 140 | 0.920 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 570 | 0.890 |
Why?
| | Prognosis | 27 | 2024 | 3793 | 0.890 |
Why?
| | Male | 114 | 2025 | 63248 | 0.890 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 27 | 0.880 |
Why?
| | Survival Rate | 22 | 2024 | 1886 | 0.880 |
Why?
| | Female | 125 | 2025 | 68274 | 0.880 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 159 | 0.800 |
Why?
| | Lymph Node Excision | 8 | 2022 | 166 | 0.790 |
Why?
| | Tretinoin | 3 | 2023 | 125 | 0.790 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 108 | 0.760 |
Why?
| | T-Lymphocytes | 8 | 2024 | 1913 | 0.750 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1094 | 0.740 |
Why?
| | Radiosurgery | 4 | 2020 | 316 | 0.720 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 11 | 0.720 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 66 | 0.720 |
Why?
| | Colorectal Neoplasms | 6 | 2024 | 731 | 0.700 |
Why?
| | Anastomotic Leak | 4 | 2024 | 38 | 0.690 |
Why?
| | Survival Analysis | 16 | 2022 | 1283 | 0.680 |
Why?
| | Adult | 65 | 2024 | 35423 | 0.670 |
Why?
| | Chemoradiotherapy | 6 | 2024 | 207 | 0.670 |
Why?
| | Splenectomy | 1 | 2020 | 59 | 0.660 |
Why?
| | Piperazines | 5 | 2014 | 326 | 0.650 |
Why?
| | Ipilimumab | 2 | 2019 | 29 | 0.650 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 53 | 0.640 |
Why?
| | Myeloid Cells | 3 | 2020 | 140 | 0.630 |
Why?
| | Ischemic Preconditioning | 3 | 2024 | 40 | 0.630 |
Why?
| | Spleen | 6 | 2017 | 518 | 0.630 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 126 | 0.610 |
Why?
| | Granulocytes | 2 | 2017 | 79 | 0.610 |
Why?
| | Pyrimidines | 5 | 2014 | 444 | 0.600 |
Why?
| | Gastrointestinal Microbiome | 8 | 2021 | 635 | 0.600 |
Why?
| | Aged, 80 and over | 28 | 2024 | 7063 | 0.590 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 69 | 0.590 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 543 | 0.580 |
Why?
| | Antineoplastic Agents | 9 | 2024 | 2043 | 0.580 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 24 | 0.580 |
Why?
| | Monocytes | 2 | 2020 | 553 | 0.570 |
Why?
| | Combined Modality Therapy | 15 | 2024 | 1213 | 0.550 |
Why?
| | CD8-Positive T-Lymphocytes | 6 | 2024 | 833 | 0.550 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 8 | 0.550 |
Why?
| | Pylorus | 1 | 2017 | 18 | 0.550 |
Why?
| | Mucous Membrane | 5 | 2024 | 122 | 0.540 |
Why?
| | Liver Neoplasms | 6 | 2024 | 637 | 0.540 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 30 | 0.530 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 170 | 0.520 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 40 | 0.520 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 111 | 0.520 |
Why?
| | Follow-Up Studies | 19 | 2024 | 4927 | 0.520 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 527 | 0.510 |
Why?
| | Leucovorin | 2 | 2019 | 69 | 0.510 |
Why?
| | Treatment Outcome | 27 | 2024 | 10256 | 0.480 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 203 | 0.460 |
Why?
| | Vitamin B Complex | 1 | 2014 | 41 | 0.460 |
Why?
| | Pancreatectomy | 5 | 2024 | 245 | 0.450 |
Why?
| | Immune Tolerance | 4 | 2016 | 349 | 0.450 |
Why?
| | Salvage Therapy | 2 | 2014 | 136 | 0.450 |
Why?
| | Esophagogastric Junction | 4 | 2024 | 48 | 0.450 |
Why?
| | Lymphocytes | 3 | 2021 | 369 | 0.440 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 173 | 0.440 |
Why?
| | Pelvis | 1 | 2014 | 102 | 0.430 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 107 | 0.430 |
Why?
| | Mutation | 9 | 2025 | 3679 | 0.430 |
Why?
| | Ear, External | 1 | 2013 | 24 | 0.420 |
Why?
| | Mohs Surgery | 1 | 2013 | 25 | 0.420 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 137 | 0.400 |
Why?
| | Biopsy | 3 | 2023 | 1093 | 0.400 |
Why?
| | Microbiota | 5 | 2024 | 724 | 0.400 |
Why?
| | Palliative Care | 1 | 2019 | 712 | 0.400 |
Why?
| | Prospective Studies | 21 | 2023 | 7070 | 0.390 |
Why?
| | Anastomosis, Surgical | 3 | 2024 | 149 | 0.390 |
Why?
| | Hematologic Diseases | 1 | 2012 | 61 | 0.390 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 626 | 0.390 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.380 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 58 | 0.380 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 291 | 0.370 |
Why?
| | Cytokines | 8 | 2021 | 1997 | 0.370 |
Why?
| | Dasatinib | 2 | 2024 | 50 | 0.370 |
Why?
| | Up-Regulation | 4 | 2012 | 850 | 0.360 |
Why?
| | Tumor Microenvironment | 6 | 2024 | 596 | 0.360 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 424 | 0.350 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 15 | 0.350 |
Why?
| | Thrombelastography | 2 | 2024 | 148 | 0.350 |
Why?
| | Granzymes | 2 | 2021 | 47 | 0.340 |
Why?
| | Homosexuality, Male | 3 | 2021 | 172 | 0.340 |
Why?
| | Benzamides | 5 | 2014 | 192 | 0.340 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 120 | 0.340 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 28 | 0.330 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2021 | 24 | 0.330 |
Why?
| | Wounds and Injuries | 4 | 2009 | 719 | 0.330 |
Why?
| | Interferon-gamma | 6 | 2019 | 759 | 0.330 |
Why?
| | Immunotherapy | 5 | 2024 | 584 | 0.320 |
Why?
| | Young Adult | 19 | 2024 | 12310 | 0.320 |
Why?
| | Medical Oncology | 4 | 2022 | 273 | 0.320 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 10 | 0.320 |
Why?
| | Butyrates | 2 | 2021 | 53 | 0.310 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 465 | 0.310 |
Why?
| | Barrett Esophagus | 3 | 2020 | 149 | 0.310 |
Why?
| | Interleukin-15 | 2 | 2021 | 82 | 0.310 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 87 | 0.300 |
Why?
| | Cell Differentiation | 5 | 2016 | 1858 | 0.300 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 380 | 0.300 |
Why?
| | Time-to-Treatment | 2 | 2024 | 182 | 0.300 |
Why?
| | Blood Preservation | 2 | 2009 | 271 | 0.300 |
Why?
| | Databases, Factual | 6 | 2024 | 1289 | 0.290 |
Why?
| | General Surgery | 2 | 2007 | 156 | 0.290 |
Why?
| | Disease-Free Survival | 8 | 2019 | 657 | 0.290 |
Why?
| | Inflammation Mediators | 2 | 2018 | 503 | 0.290 |
Why?
| | Colon | 3 | 2021 | 246 | 0.280 |
Why?
| | Nomograms | 2 | 2019 | 48 | 0.280 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.280 |
Why?
| | Antigens, Neoplasm | 3 | 2024 | 309 | 0.280 |
Why?
| | Dysbiosis | 3 | 2021 | 166 | 0.270 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 996 | 0.270 |
Why?
| | Immunocompromised Host | 1 | 2008 | 198 | 0.270 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 185 | 0.270 |
Why?
| | Time Factors | 12 | 2024 | 6579 | 0.270 |
Why?
| | Cells, Cultured | 9 | 2021 | 4063 | 0.260 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 3 | 0.260 |
Why?
| | Population Surveillance | 2 | 2021 | 428 | 0.260 |
Why?
| | Lymphangioma | 1 | 2006 | 7 | 0.260 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 182 | 0.260 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 19 | 0.260 |
Why?
| | Mice | 24 | 2024 | 16583 | 0.260 |
Why?
| | Th2 Cells | 2 | 2005 | 169 | 0.260 |
Why?
| | Transplantation Immunology | 1 | 2005 | 33 | 0.250 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 379 | 0.250 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 90 | 0.250 |
Why?
| | Mentors | 1 | 2007 | 174 | 0.250 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 608 | 0.250 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 100 | 0.250 |
Why?
| | Exome | 2 | 2017 | 219 | 0.250 |
Why?
| | Mice, Inbred BALB C | 6 | 2024 | 1230 | 0.250 |
Why?
| | Catheter Ablation | 4 | 2016 | 324 | 0.250 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 8 | 0.250 |
Why?
| | Immunity, Innate | 4 | 2021 | 804 | 0.250 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 264 | 0.240 |
Why?
| | Hepatectomy | 3 | 2024 | 207 | 0.240 |
Why?
| | B-Lymphocytes | 3 | 2017 | 813 | 0.240 |
Why?
| | Interleukin-10 | 3 | 2016 | 299 | 0.240 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 16 | 0.240 |
Why?
| | Radiation Injuries | 2 | 2021 | 139 | 0.240 |
Why?
| | Virus Replication | 5 | 2017 | 448 | 0.240 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 108 | 0.230 |
Why?
| | Tumor Hypoxia | 1 | 2024 | 6 | 0.230 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 35 | 0.230 |
Why?
| | B7-H1 Antigen | 2 | 2024 | 175 | 0.230 |
Why?
| | Metastasectomy | 1 | 2024 | 21 | 0.230 |
Why?
| | Th1 Cells | 2 | 2019 | 135 | 0.230 |
Why?
| | Macrophage Activation | 1 | 2005 | 178 | 0.230 |
Why?
| | Signal Transduction | 9 | 2023 | 4867 | 0.220 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 25 | 0.220 |
Why?
| | Mice, Nude | 2 | 2024 | 680 | 0.220 |
Why?
| | Lymphocyte Count | 5 | 2017 | 149 | 0.220 |
Why?
| | Interferon-alpha | 3 | 2015 | 191 | 0.220 |
Why?
| | Carcinoma | 2 | 2006 | 214 | 0.220 |
Why?
| | Ruminococcus | 2 | 2021 | 9 | 0.220 |
Why?
| | Erythrocytes | 1 | 2009 | 669 | 0.220 |
Why?
| | Adolescent | 15 | 2019 | 20241 | 0.220 |
Why?
| | Flow Cytometry | 6 | 2017 | 1147 | 0.220 |
Why?
| | Feces | 4 | 2021 | 430 | 0.220 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1061 | 0.220 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 34 | 0.210 |
Why?
| | Esophageal Stenosis | 1 | 2024 | 51 | 0.210 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 4 | 0.210 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 435 | 0.210 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 200 | 0.210 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 68 | 0.210 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 9 | 0.210 |
Why?
| | Lysophospholipids | 1 | 2023 | 71 | 0.200 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 460 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 93 | 0.200 |
Why?
| | Specialties, Surgical | 1 | 2023 | 77 | 0.200 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 6 | 0.200 |
Why?
| | Intestines | 2 | 2017 | 347 | 0.200 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 174 | 0.200 |
Why?
| | Animals | 27 | 2024 | 34708 | 0.200 |
Why?
| | Cell Count | 2 | 2017 | 318 | 0.200 |
Why?
| | Preoperative Care | 3 | 2018 | 343 | 0.200 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1174 | 0.200 |
Why?
| | Cohort Studies | 6 | 2024 | 5400 | 0.200 |
Why?
| | Patient Selection | 3 | 2014 | 671 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2530 | 0.200 |
Why?
| | Ampulla of Vater | 2 | 2024 | 39 | 0.200 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 15 | 0.190 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 23 | 0.190 |
Why?
| | Bacteria | 3 | 2018 | 812 | 0.190 |
Why?
| | Cryosurgery | 2 | 2019 | 54 | 0.190 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 141 | 0.190 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 67 | 0.190 |
Why?
| | HIV Seropositivity | 1 | 2022 | 118 | 0.190 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 33 | 0.190 |
Why?
| | Esophagoscopy | 2 | 2020 | 197 | 0.190 |
Why?
| | Critical Pathways | 1 | 2022 | 81 | 0.190 |
Why?
| | Gastrectomy | 2 | 2024 | 99 | 0.190 |
Why?
| | Acinetobacter | 1 | 2021 | 13 | 0.190 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 166 | 0.180 |
Why?
| | Disease Progression | 2 | 2022 | 2607 | 0.180 |
Why?
| | Carcinoma in Situ | 1 | 2001 | 45 | 0.180 |
Why?
| | Seminoma | 1 | 2021 | 17 | 0.180 |
Why?
| | Glucose | 3 | 2020 | 976 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
| | Firmicutes | 1 | 2021 | 18 | 0.180 |
Why?
| | Risk Factors | 12 | 2024 | 9804 | 0.180 |
Why?
| | Transcriptome | 2 | 2025 | 875 | 0.180 |
Why?
| | Carcinoma, Lobular | 1 | 2001 | 46 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 52 | 0.180 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2001 | 80 | 0.180 |
Why?
| | Interleukin-2 | 5 | 2022 | 428 | 0.180 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 873 | 0.170 |
Why?
| | Diarrhea | 3 | 2008 | 179 | 0.170 |
Why?
| | Bacterial Translocation | 2 | 2019 | 38 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.170 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 16 | 0.170 |
Why?
| | Delivery of Health Care | 2 | 2021 | 896 | 0.170 |
Why?
| | Receptors, CCR | 1 | 2020 | 7 | 0.170 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 42 | 0.170 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 66 | 0.170 |
Why?
| | Interleukins | 2 | 2019 | 245 | 0.170 |
Why?
| | Platelet Count | 1 | 2020 | 83 | 0.170 |
Why?
| | Guidelines as Topic | 2 | 2018 | 260 | 0.170 |
Why?
| | Basophils | 1 | 2020 | 71 | 0.170 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 85 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 207 | 0.160 |
Why?
| | Cell Proliferation | 6 | 2021 | 2344 | 0.160 |
Why?
| | Dacarbazine | 4 | 2012 | 99 | 0.160 |
Why?
| | Scalp | 1 | 2019 | 35 | 0.160 |
Why?
| | Patient Care Planning | 2 | 2016 | 152 | 0.160 |
Why?
| | Apoptosis | 5 | 2021 | 2485 | 0.160 |
Why?
| | Surgeons | 1 | 2023 | 279 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2021 | 106 | 0.160 |
Why?
| | Decision Making | 2 | 2019 | 837 | 0.160 |
Why?
| | Cell Line, Tumor | 6 | 2024 | 3114 | 0.160 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 9 | 0.160 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 4 | 0.160 |
Why?
| | Germ-Free Life | 1 | 2019 | 34 | 0.160 |
Why?
| | Sclerotherapy | 1 | 2019 | 18 | 0.160 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 190 | 0.160 |
Why?
| | Haploinsufficiency | 1 | 2019 | 47 | 0.160 |
Why?
| | Leukocyte Count | 1 | 2020 | 328 | 0.160 |
Why?
| | Breast Neoplasms | 2 | 2001 | 2116 | 0.160 |
Why?
| | CD4 Antigens | 2 | 2011 | 137 | 0.160 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 14 | 0.160 |
Why?
| | Photochemotherapy | 1 | 2019 | 30 | 0.160 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 48 | 0.160 |
Why?
| | Nutritional Support | 1 | 2019 | 31 | 0.160 |
Why?
| | Stomach | 3 | 2024 | 109 | 0.160 |
Why?
| | Abdominal Neoplasms | 2 | 2010 | 32 | 0.160 |
Why?
| | Mastocytosis | 1 | 2019 | 13 | 0.160 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 45 | 0.160 |
Why?
| | Intestinal Perforation | 1 | 2019 | 44 | 0.160 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 88 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 320 | 0.160 |
Why?
| | Immunophenotyping | 2 | 2017 | 311 | 0.160 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 226 | 0.160 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 70 | 0.160 |
Why?
| | Th17 Cells | 1 | 2019 | 81 | 0.160 |
Why?
| | Survivors | 2 | 2015 | 458 | 0.150 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 48 | 0.150 |
Why?
| | Dilatation | 1 | 2019 | 62 | 0.150 |
Why?
| | Skin Pigmentation | 1 | 2019 | 49 | 0.150 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 10 | 0.150 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 302 | 0.150 |
Why?
| | Brachytherapy | 1 | 2019 | 103 | 0.150 |
Why?
| | Esophagus | 1 | 2020 | 253 | 0.150 |
Why?
| | Fibrosis | 1 | 2021 | 518 | 0.150 |
Why?
| | Hospitals | 2 | 2021 | 628 | 0.150 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 140 | 0.150 |
Why?
| | Septins | 1 | 2018 | 43 | 0.150 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.150 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 22 | 0.150 |
Why?
| | HIV | 1 | 2019 | 223 | 0.140 |
Why?
| | Risk Assessment | 4 | 2024 | 3290 | 0.140 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 271 | 0.140 |
Why?
| | Down-Regulation | 1 | 2020 | 639 | 0.140 |
Why?
| | Viral Tropism | 1 | 2017 | 28 | 0.140 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 24 | 0.140 |
Why?
| | Cell Movement | 4 | 2022 | 935 | 0.140 |
Why?
| | Food, Formulated | 1 | 1997 | 16 | 0.140 |
Why?
| | Deglutition Disorders | 1 | 2019 | 129 | 0.140 |
Why?
| | Enteral Nutrition | 2 | 2010 | 186 | 0.140 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 24 | 0.140 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 27 | 0.140 |
Why?
| | Laser Therapy | 1 | 2019 | 127 | 0.140 |
Why?
| | Liver | 4 | 2016 | 1835 | 0.140 |
Why?
| | src-Family Kinases | 1 | 2017 | 94 | 0.140 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 138 | 0.140 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 50 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 594 | 0.140 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 215 | 0.140 |
Why?
| | Gastric Emptying | 1 | 2017 | 39 | 0.140 |
Why?
| | Arginine | 1 | 1998 | 254 | 0.130 |
Why?
| | United States | 12 | 2024 | 13992 | 0.130 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 40 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 195 | 0.130 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 31 | 0.130 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
| | Immunologic Memory | 2 | 2016 | 337 | 0.130 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 829 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 211 | 0.130 |
Why?
| | Nutritional Status | 1 | 2019 | 325 | 0.130 |
Why?
| | Perioperative Care | 1 | 2018 | 150 | 0.130 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 17 | 0.130 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 97 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 205 | 0.130 |
Why?
| | Mortality | 1 | 2018 | 310 | 0.130 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 67 | 0.130 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 80 | 0.130 |
Why?
| | Bystander Effect | 1 | 2016 | 16 | 0.130 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 1968 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1367 | 0.130 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 130 | 0.130 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 25 | 0.130 |
Why?
| | Germinal Center | 1 | 2016 | 54 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 78 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 229 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 411 | 0.120 |
Why?
| | Exons | 3 | 2019 | 332 | 0.120 |
Why?
| | Morbidity | 3 | 2023 | 301 | 0.120 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 51 | 0.120 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 13 | 0.120 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 14 | 0.120 |
Why?
| | Postoperative Care | 1 | 1997 | 246 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 822 | 0.120 |
Why?
| | Adenoma | 1 | 2017 | 210 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1204 | 0.120 |
Why?
| | Ileus | 1 | 2014 | 12 | 0.120 |
Why?
| | Phosphoproteins | 1 | 2017 | 326 | 0.120 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 8 | 0.120 |
Why?
| | Biomarkers | 3 | 2024 | 3878 | 0.120 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 83 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 799 | 0.120 |
Why?
| | Quality of Life | 3 | 2019 | 2711 | 0.120 |
Why?
| | Viral Load | 5 | 2018 | 448 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1102 | 0.120 |
Why?
| | Vinblastine | 2 | 2012 | 69 | 0.120 |
Why?
| | Endosonography | 1 | 2016 | 141 | 0.120 |
Why?
| | Ethanol | 1 | 2019 | 584 | 0.110 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 267 | 0.110 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 62 | 0.110 |
Why?
| | Dietary Supplements | 1 | 1998 | 533 | 0.110 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 929 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 738 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2357 | 0.110 |
Why?
| | Blood Cell Count | 1 | 2013 | 54 | 0.110 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 182 | 0.110 |
Why?
| | Fluorouracil | 2 | 2019 | 198 | 0.110 |
Why?
| | Pilot Projects | 1 | 2018 | 1548 | 0.110 |
Why?
| | Tumor Burden | 4 | 2022 | 284 | 0.110 |
Why?
| | RNA, Viral | 3 | 2013 | 622 | 0.110 |
Why?
| | Colectomy | 3 | 2008 | 94 | 0.110 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 90 | 0.100 |
Why?
| | Registries | 1 | 2021 | 1916 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 468 | 0.100 |
Why?
| | Mice, Knockout | 4 | 2024 | 2774 | 0.100 |
Why?
| | Cisplatin | 2 | 2012 | 292 | 0.100 |
Why?
| | Oligopeptides | 1 | 2014 | 256 | 0.100 |
Why?
| | Sensitivity and Specificity | 4 | 2015 | 1842 | 0.100 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 72 | 0.100 |
Why?
| | HIV Antibodies | 1 | 2013 | 58 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2273 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 9 | 0.100 |
Why?
| | Ablation Techniques | 1 | 2012 | 31 | 0.100 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 513 | 0.100 |
Why?
| | Hospital Mortality | 2 | 2016 | 853 | 0.100 |
Why?
| | Biological Therapy | 1 | 2012 | 30 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 147 | 0.100 |
Why?
| | Palatine Tonsil | 3 | 2017 | 45 | 0.100 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 131 | 0.100 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 103 | 0.100 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 164 | 0.090 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 105 | 0.090 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 38 | 0.090 |
Why?
| | Gene Expression Profiling | 3 | 2025 | 1696 | 0.090 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 521 | 0.090 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 19 | 0.090 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.090 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 182 | 0.090 |
Why?
| | Macrophages | 2 | 2001 | 1456 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 607 | 0.090 |
Why?
| | Ligands | 2 | 2023 | 616 | 0.090 |
Why?
| | Extremities | 2 | 2022 | 129 | 0.090 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1504 | 0.090 |
Why?
| | Antigens, CD | 2 | 2015 | 480 | 0.090 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 5 | 0.090 |
Why?
| | Endocytosis | 1 | 2011 | 162 | 0.090 |
Why?
| | Cell Separation | 2 | 2010 | 312 | 0.090 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 258 | 0.090 |
Why?
| | Interleukin-23 | 1 | 2010 | 19 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2016 | 731 | 0.090 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 172 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 322 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5282 | 0.090 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 37 | 0.090 |
Why?
| | Heparin | 1 | 2012 | 252 | 0.080 |
Why?
| | Gastric Fistula | 1 | 2010 | 9 | 0.080 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 13 | 0.080 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 295 | 0.080 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 114 | 0.080 |
Why?
| | Escherichia coli | 1 | 2014 | 784 | 0.080 |
Why?
| | Antiviral Agents | 1 | 2015 | 708 | 0.080 |
Why?
| | Viremia | 1 | 2010 | 133 | 0.080 |
Why?
| | Genomics | 2 | 2025 | 716 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 241 | 0.080 |
Why?
| | Double-Blind Method | 4 | 2014 | 1864 | 0.080 |
Why?
| | Rosaniline Dyes | 3 | 2007 | 11 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1435 | 0.080 |
Why?
| | Cell Transplantation | 1 | 2009 | 35 | 0.080 |
Why?
| | Odds Ratio | 3 | 2019 | 1021 | 0.080 |
Why?
| | Immunoglobulins | 2 | 2023 | 158 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2009 | 61 | 0.080 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 70 | 0.080 |
Why?
| | ROC Curve | 2 | 2024 | 501 | 0.080 |
Why?
| | Phenotype | 5 | 2019 | 3062 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1061 | 0.080 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 24 | 0.080 |
Why?
| | Gastrostomy | 1 | 2010 | 113 | 0.080 |
Why?
| | Hyalin | 1 | 2008 | 7 | 0.080 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 9 | 0.080 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 376 | 0.080 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 149 | 0.080 |
Why?
| | Age Factors | 3 | 2019 | 3137 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 67 | 0.070 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 79 | 0.070 |
Why?
| | Interleukin-4 | 2 | 2007 | 214 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 703 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 861 | 0.070 |
Why?
| | ras Proteins | 1 | 2009 | 150 | 0.070 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 137 | 0.070 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 391 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1318 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 225 | 0.070 |
Why?
| | Logistic Models | 4 | 2016 | 1966 | 0.070 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3336 | 0.070 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2024 | 485 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 549 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 76 | 0.070 |
Why?
| | Length of Stay | 3 | 2019 | 1128 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2008 | 163 | 0.070 |
Why?
| | Anticoagulants | 1 | 2012 | 622 | 0.070 |
Why?
| | Interleukin-6 | 4 | 1999 | 716 | 0.070 |
Why?
| | Interleukin-1beta | 2 | 2019 | 376 | 0.070 |
Why?
| | Career Mobility | 1 | 2007 | 68 | 0.070 |
Why?
| | Critical Care | 1 | 2012 | 551 | 0.070 |
Why?
| | Phylogeny | 2 | 2024 | 844 | 0.070 |
Why?
| | Blood Transfusion | 1 | 2009 | 294 | 0.070 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.070 |
Why?
| | Watchful Waiting | 2 | 2018 | 66 | 0.070 |
Why?
| | DNA, Bacterial | 2 | 2019 | 324 | 0.070 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.070 |
Why?
| | New York | 2 | 2023 | 127 | 0.070 |
Why?
| | Laparotomy | 1 | 2007 | 108 | 0.070 |
Why?
| | History, 20th Century | 1 | 2007 | 295 | 0.070 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1697 | 0.070 |
Why?
| | Computational Biology | 2 | 2024 | 588 | 0.060 |
Why?
| | Collagen | 1 | 2008 | 433 | 0.060 |
Why?
| | Interleukin-17 | 2 | 2019 | 107 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 48 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 877 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2024 | 428 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 638 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 267 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 802 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 54 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 34 | 0.060 |
Why?
| | Culture Media | 1 | 2005 | 168 | 0.060 |
Why?
| | Obesity, Morbid | 1 | 2008 | 241 | 0.060 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 407 | 0.060 |
Why?
| | Chromones | 1 | 2024 | 46 | 0.060 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 27 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2005 | 2702 | 0.060 |
Why?
| | Faculty, Medical | 1 | 2007 | 263 | 0.060 |
Why?
| | Quality Improvement | 1 | 2012 | 1103 | 0.060 |
Why?
| | Nitric Oxide | 2 | 2001 | 892 | 0.060 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 270 | 0.060 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 36 | 0.060 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 249 | 0.060 |
Why?
| | Azepines | 1 | 2024 | 87 | 0.060 |
Why?
| | Morpholines | 1 | 2024 | 126 | 0.060 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 52 | 0.060 |
Why?
| | Leadership | 1 | 2007 | 356 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 30 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 480 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2024 | 230 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 153 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 14 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 294 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 41 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 58 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 153 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 96 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 42 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 936 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 307 | 0.050 |
Why?
| | Child | 4 | 2019 | 20860 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 9 | 0.050 |
Why?
| | Hypoglycemia | 1 | 2007 | 427 | 0.050 |
Why?
| | Corticosterone | 1 | 2003 | 214 | 0.050 |
Why?
| | Technetium | 1 | 2001 | 11 | 0.050 |
Why?
| | Injections, Intradermal | 1 | 2001 | 13 | 0.050 |
Why?
| | Dietary Proteins | 1 | 2003 | 131 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 72 | 0.050 |
Why?
| | Leptin | 1 | 2003 | 217 | 0.050 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2001 | 6 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 332 | 0.050 |
Why?
| | Propionates | 1 | 2021 | 34 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2001 | 126 | 0.050 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 38 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 259 | 0.050 |
Why?
| | Mediastinoscopy | 1 | 2021 | 5 | 0.050 |
Why?
| | Veterans | 1 | 2013 | 1397 | 0.050 |
Why?
| | NF-kappa B | 1 | 2005 | 687 | 0.050 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 382 | 0.050 |
Why?
| | Precision Medicine | 2 | 2016 | 386 | 0.050 |
Why?
| | Biopsy, Needle | 1 | 2001 | 192 | 0.050 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 285 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 255 | 0.040 |
Why?
| | Workload | 1 | 2002 | 154 | 0.040 |
Why?
| | Acetates | 1 | 2021 | 99 | 0.040 |
Why?
| | Cholangiography | 1 | 2000 | 17 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 50 | 0.040 |
Why?
| | Glycoproteins | 2 | 2015 | 340 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 235 | 0.040 |
Why?
| | Probability | 1 | 2001 | 313 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2001 | 167 | 0.040 |
Why?
| | Thoracoscopy | 1 | 2020 | 53 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 18 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 20 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 425 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 946 | 0.040 |
Why?
| | Quality of Health Care | 3 | 2012 | 610 | 0.040 |
Why?
| | Body Mass Index | 1 | 2008 | 2250 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 987 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 79 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 37 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 136 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 214 | 0.040 |
Why?
| | Eating | 2 | 2003 | 366 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 559 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 38 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 864 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1285 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 288 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 74 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 446 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 112 | 0.040 |
Why?
| | Montana | 1 | 2018 | 18 | 0.040 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 24 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2022 | 642 | 0.040 |
Why?
| | Mitogens | 1 | 1998 | 58 | 0.040 |
Why?
| | Keratins | 2 | 2010 | 176 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2019 | 239 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 117 | 0.040 |
Why?
| | Cachexia | 1 | 1999 | 60 | 0.040 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 158 | 0.040 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 109 | 0.040 |
Why?
| | Pedigree | 1 | 2019 | 491 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 510 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 334 | 0.040 |
Why?
| | Perioperative Period | 1 | 2017 | 49 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 731 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2018 | 187 | 0.040 |
Why?
| | Jejunostomy | 1 | 1997 | 12 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1424 | 0.030 |
Why?
| | Dinoprostone | 1 | 1998 | 188 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 151 | 0.030 |
Why?
| | Femoral Fractures | 1 | 1998 | 74 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 109 | 0.030 |
Why?
| | Operative Time | 1 | 2017 | 120 | 0.030 |
Why?
| | Candidiasis | 1 | 1997 | 57 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 19 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 21 | 0.030 |
Why?
| | Liver Circulation | 1 | 2016 | 19 | 0.030 |
Why?
| | Infection Control | 1 | 1998 | 138 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 81 | 0.030 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 37 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 249 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 602 | 0.030 |
Why?
| | Neck | 1 | 2017 | 92 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 395 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 211 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 5 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 94 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 310 | 0.030 |
Why?
| | Histones | 1 | 2021 | 584 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 18 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 422 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 211 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 24 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 957 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 80 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1192 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2087 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 159 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 479 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 421 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 83 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 14 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 5036 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 860 | 0.030 |
Why?
| | Virion | 1 | 2015 | 83 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 154 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 120 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1516 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 674 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 454 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 582 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 88 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 426 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 571 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 26 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 105 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 973 | 0.030 |
Why?
| | Colitis | 1 | 2016 | 240 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 674 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 129 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 778 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3357 | 0.030 |
Why?
| | Inflammation | 2 | 2019 | 2696 | 0.030 |
Why?
| | Hemorrhage | 1 | 1998 | 658 | 0.030 |
Why?
| | Phosphorylation | 1 | 1998 | 1686 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 311 | 0.030 |
Why?
| | Caspase 1 | 1 | 2014 | 143 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 269 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 333 | 0.030 |
Why?
| | Autoantigens | 1 | 2016 | 414 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 10 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3047 | 0.030 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 47 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1526 | 0.030 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 58 | 0.030 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 80 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 33 | 0.030 |
Why?
| | AIDS Vaccines | 1 | 2013 | 47 | 0.030 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 29 | 0.030 |
Why?
| | International Agencies | 1 | 2012 | 29 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2013 | 185 | 0.030 |
Why?
| | Internship and Residency | 1 | 2002 | 1052 | 0.030 |
Why?
| | Thoracotomy | 1 | 2012 | 75 | 0.020 |
Why?
| | Homeostasis | 1 | 2016 | 605 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 87 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1021 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 217 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 370 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 278 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 318 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 54 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 131 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 181 | 0.020 |
Why?
| | APACHE | 1 | 2012 | 65 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 340 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 26 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1175 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 303 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 568 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 262 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 760 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 293 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 273 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 261 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 371 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 21 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1477 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 23 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 579 | 0.020 |
Why?
| | Risk | 1 | 2013 | 867 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1221 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1085 | 0.020 |
Why?
| | Universities | 1 | 2013 | 404 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 577 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 171 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 18 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 142 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2635 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1717 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 69 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 417 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 14 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 52 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2050 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 39 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 140 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 131 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 140 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 24 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 837 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 169 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 40 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 48 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 91 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 871 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2846 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 75 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 90 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 264 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1950 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1480 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 269 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2082 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 245 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 978 | 0.020 |
Why?
| | Swine | 1 | 2010 | 740 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 522 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 654 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 4 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 216 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3999 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 246 | 0.020 |
Why?
| | Whole Body Imaging | 1 | 2006 | 20 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1045 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 185 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 319 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2523 | 0.020 |
Why?
| | Infant | 1 | 2019 | 8997 | 0.010 |
Why?
| | Radiotherapy | 1 | 2006 | 186 | 0.010 |
Why?
| | Patient Discharge | 1 | 2011 | 858 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 404 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2157 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 105 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 60 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 67 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 26 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4445 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 82 | 0.010 |
Why?
| | Work Schedule Tolerance | 1 | 2002 | 42 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 352 | 0.010 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2002 | 89 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 55 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 29 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 40 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 279 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 219 | 0.010 |
Why?
| | Continuity of Patient Care | 1 | 2002 | 278 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 30 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 62 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 183 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 53 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 1974 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 2847 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 1090 | 0.010 |
Why?
| | RNA | 1 | 2001 | 877 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 513 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 6256 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1330 | 0.010 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|